Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Apr 21, 2015; 21(15): 4696-4706
Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4696
Table 4 Alanine aminotransferase level change at each testing point
GroupTriple therapyALT level (U/L)
Dual therapyALT level (U/L)
nAt baselineAt end of treatmentAt 24 wk after the end of treatmentP value1nAt baselineAt end of treatmentAt 24 wk after the end of treatmentP value1
All patients8856.6 ± 4.125.9 ± 2.422.7 ± 1.8< 0.00112264.1 ± 4.729.4 ± 4.035.3 ± 3.0< 0.001
Treatment outcome
SVR7554.3 ± 4.325.4 ± 2.717.8 ± 1.1< 0.0015274.0 ± 7.318.8 ± 1.614.9 ± 0.8< 0.001
Non-SVR1369.8 ± 12.228.8 ± 3.850.6 ± 6.00.1477056.8 ± 4.937.4 ± 6.750.4 ± 4.30.169
Baseline ALT level
≥ 40 U/L4981.4 ± 5.132.9 ± 3.528.5 ± 2.8< 0.0017884.3 ± 5.436.6 ± 5.940.0 ± 4.2< 0.001
< 40 U/L3925.4 ± 1.217.1 ± 2.615.4 ± 1.3< 0.0014428.3 ± 1.116.0 ± 1.726.8 ± 3.00.637
Previous treatment response
Naïve/Prior relapse5956.5 ± 5.225.5 ± 2.719.4 ± 1.5< 0.001
Prior NVR2756.7 ± 7.521.0 ± 2.528.6 ± 4.5< 0.001
IL28B SNP (rs8099917)
TT4956.9 ± 5.426.6 ± 3.817.4 ± 1.3< 0.0017363.6 ± 5.418.9 ± 1.425.9 ± 2.4< 0.001
TG/GG3956.2 ± 6.524.9 ± 2.629.2 ± 3.5< 0.0013165.9 ± 9.438.8 ± 6.250.9 ± 5.20.073
Stage of fibrosis
F0-25251.6 ± 5.223.1 ± 3.217.6 ± 1.5< 0.0017663.4 ± 5.421.1 ± 1.725.4 ± 2.4< 0.001
F3-41268.8 ± 11.632.3 ± 5.627.5 ± 5.40.008893.0 ± 25.834.8 ± 7.646.5 ± 11.80.172